Reneo Pharmaceuticals Inc

About Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals (NASDAQ:RPHM) is focused on developing treatments for patients with rare genetic mitochondrial diseases. Their main project is REN001, an oral therapy under investigation for several indications, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. By advancing this pipeline, Reneo aims to address significant unmet medical needs and improve the quality of life for individuals with these challenging conditions. The company is dedicated to pioneering research, ensuring rigorous clinical trials, and collaborating with stakeholders to bring transformative therapies to market. Reneo's commitment lies in creating solutions that offer hope and tangible benefits to patients suffering from these debilitating diseases.

What is Reneo Pharmaceuticals Inc known for?

Snapshot

Year founded

Employees

San Diego, United States

Head office

Loading Map...

Operations

All Locations

San Diego, US

Products and/or services of Reneo Pharmaceuticals Inc

REN001: A pioneering project focused on developing a novel treatment for primary mitochondrial myopathies, aiming to improve muscle function in affected patients.
Advancement of therapies: Focus on research for metabolic and rare genetic disorders, utilizing scientific insights to create impactful treatment options.
Strategic partnerships: Collaborations with academic institutions and biotech firms to enhance discovery and development of cutting-edge therapeutic solutions.
Clinical trials management: Execution and oversight of clinical studies to assess efficacy and safety of investigational therapies, ensuring compliance with regulatory standards.
Patient-focused initiatives: Engagement with patient communities and advocacy groups to incorporate feedback and improve treatment approaches.
Expansion of intellectual property: Development and protection of proprietary technologies and therapeutic compounds to secure competitive advantage in the market.